Many pathological cells generate and transmit higher forces, compared to normal cells, in diseases including cancer, vascular dementia, chronic kidney disease, and hemiplagia. The high forces facilitate efficient internalization of surface molecules bound to their binding partners. We propose a tension-sensitive drug release system, where drug will be released from an implanted drug repository only when high tension is generated by pathological cells, so that the drug will only be ingested by pathological cells but not normal cells. As a result, only diseased cells will be killed by the drug. Because adverse effects of the current therapies mostly arise from the insufficient selectivity in terms of cell killing, will lead to enhanced treatment efficacy while reducing the adverse effects, thereby improving both survival rates and the quality of life for patients. Overall, our drug release system will be the first of its kind to selectively target abnormal cells based on the stronger force generated by the hyper-contractile diseased cells.
Abnormally high force generation has been observed in abnormal cells contributing to diseases including cancer, vascular dementia, chronic kidney disease, and hemiplegia. In this project we propose to develop a tension-sensitive drug release system, where drug will be released from an implanted drug repository only when high tension is generated by pathological cells. The built-in biophysical selectivity of the proposed drug release system can facilitate the drug ingestion only by pathological cells capable of generating enough forces, thereby accomplishing treatment efficacy, reducing the adverse effects and improving the life quality for patients.